5 articles with Autobahn Therapeutics
Scott Giacobello Appointed to Board of Directors Scott Forrest, Ph.D., Promoted to Chief Financial Officer
Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced that Kevin Finney, chief executive officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 12, 2021 at 12:10 p.m. ET. About Autobahn Therapeutics Autobahn Therapeutics is focused on restoring hope for people affected by CNS disorders. Autobahn is leveraging i
Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced the appointment of Scott Forrest, Ph.D., to the company’s newly created position of chief business officer. In this role, Dr. Forrest will oversee corporate development, portfolio strategic planning and financial strategy, and will report to Kevin Finney, chief executive officer. “Scott is a seaso
Autobahn Therapeutics Launches with $76 Million Series B Financing to Develop Next Generation Therapies for CNS Disorders
Financing Co-Led by ARCH Venture Partners and Cowen Healthcare Investments
This morning, the company officially launched with a Series B funding round backed by some of the biggest names in the life sciences, including Bristol Myers Squibb, Biogen and Pfizer.